Risk Factors and Predictors of Outcome in Patients with Cancer and Breakthrough Candidemia
Open Access
- 15 June 2001
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (12) , 1713-1717
- https://doi.org/10.1086/320757
Abstract
Hematogenous candidiasis adds substantially to the morbidity and mortality rates of patients with cancer. Little is known about the risk factors andKeywords
This publication has 18 references indexed in Scilit:
- Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazoleMycoses, 1999
- Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcomeJournal of Antimicrobial Chemotherapy, 1998
- Hazards of inadequate fluconazole dosage to treat deep-seated or systemic Candida albicans infectionJournal of Infection, 1997
- Breakthrough Candidemia in Neutropenic PatientsClinical Infectious Diseases, 1997
- Editorial Response: Catheters and CandidemiaClinical Infectious Diseases, 1996
- Failure of Systemic Empirical Treatment with Amphotericin B to Prevent Candidemia in Neutropenic Patients with CancerClinical Infectious Diseases, 1996
- Predominant pathogens in hospital infectionsJournal of Antimicrobial Chemotherapy, 1992
- The APACHE III Prognostic SystemChest, 1991
- Hospital-acquired candidemia. The attributable mortality and excess length of stayArchives of internal medicine (1960), 1988
- Amphotericin B-resistant yeast infection in severely immunocompromised patientsThe American Journal of Medicine, 1988